65,437 trials
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants Who Developed Psoriatic Arthritis (PsA) — 47.4; 35.7; 17.3; 10.3 Percentage of participants
Allergy · Asthma
Primary: Proportion of Participants Who Discontinue Study — 7.1 Percentage of Participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c) — -1.12; -1.22 percentage of HbA1c — p=0.3709
Orthostatic Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure — 98; 97; 102; 87 mmHg
Diabetes Mellitus Type 2 · Diabetes Mellitus, Type 1 · Primary Care Provider
Primary: A1c — 10.1; 9.32; 8.82; 8.36 percentage of Hb that is glycosylated
Phenylketonuria
Primary: Plasma Phenylalanine Level (mg/dl) — 18.0; 17.2 mg/dl — p=>0.05
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
Total Knee Arthroplasty(TKA) · Total Knee Replacement
Primary: Knee Range of Motion (ROM) — 119; 120 degree
Fragile X Syndrome
Primary: Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the Aberrant Behavior Checklist-Community Edition (ABC-CFX) Total Score in Stratum I Patients…
Rectal Adenocarcinoma · Stage II Rectal Cancer AJCC v7 · Stage III Rectal Cancer AJCC v7
Primary: Pathologic Complete Response Rate — 17 percentage of participants
Alzheimer's Disease
Primary: Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation — 15; 18.5 Percentage of participants
Anxiety; Generalized · Breast Diseases · Surgery
Primary: Anxiety Reduction — 0.89; .74 units on a scale
HIV Infections · Proteinuria
Primary: Patients With Reduced or Resolved Proteinuria — 20 participants
Breast Cancer
Primary: Disease-free Survival — 57; 69 percentage of participants
Infections, Papillomavirus
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 45; 15; 2; 0 Participants